Following the initial period of antithrombotic therapy for patients with AF undergoing elective PCI without high-risk features

Recommendation 26. If age is < 65 and CHADS2 = 0, we recommend long-term therapy with either ASA alone or, if high-risk clinical or angiographic features of ischemic events develop and low risk of bleeding, ASA plus a P2Y12 inhibitor (Strong Recommendation, High Quality Evidence); or

After the initial period of antithrombotic therapy for patients with AF without high-risk features who undergo elective PCI, if age is 65 years or older or CHADS2 ≥ 1 we recommend long-term therapy with either OAC alone (Strong Recommendation; High-Quality Evidence) or, if high-risk clinical or angiographic features for ischemic events develop and low risk of bleeding, OAC and single antiplatelet therapy with aspirin or a P2Y12 inhibitor (Weak Recommendation; Low-Quality Evidence).

Practical tip. All patients should receive ASA 81 mg (or a minimum of 160 mg if ASA-naive) on the day of the PCI procedure.